



27th Meeting of the IBCN
September 19th – September 21st, 2024

-

at
Kursaal, Bern
Bern, Switzerland

Platinum Sponsors:



Platinum Sponsors:



THE
BLADDER CANCER
COMPANY™



Gold Sponsor:



Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern



Abstract Review Committee:

Veronika Bahlinger
Gautier Marcq
Joep de Jong
Clémentine Le Magnen
Andrew Mason
Jasper Hof
David Mueller
Sia Viborg Lindskrog

Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern

THURSDAY, SEPTEMBER 19th, 2024

19:00 Welcome Dinner

We will have the traditional “get-together” the evening prior to the meeting. This is an informal gathering at the conference hotel (Swissôtel Kursaal). Drinks will begin at 7 pm followed by a buffet dinner at 8 pm.

FRIDAY, SEPTEMBER 20th, 2024

***Breakfast on your own in the hotel **BEFORE** meeting

Introduction		
07:30	Registration	
08:00	Welcome to IBCN Meeting	Roman Nawroth
08:05	Welcome to Bern	Roland Seiler

Abstract Session I (Preclinical Models and Genomic Insights)		
Chairs: Andrew Mason, Clémentine Le Magnen		
08:15	Guidance of adjuvant instillation in intermediate risk non-muscle invasive bladder cancer by drug screens in patient derived organoids – preliminary data	Martin Egger
08:24	A patient-derived bladder cancer organoid biobank for translational research and precision oncology	Michele Garioni
08:33	Assessing the feasibility of BK polyomavirus infections as an initiating event for bladder cancer via APOBEC3A/B “paramutagenesis”.	Simon Baker
08:42	Whole genome sequencing of 358 urothelial carcinoma highlights copy number alterations as the trigger for malignancy	Andrew Mason
08:51	Comprehensive genomic characterization of early-stage bladder cancer	Philippe Lamy

Keynote I		
		Chair: Roland Seiler
9:15	Inferring tumor evolution from single-cell data	Niko Beerenwinkel
9:45	Discussion	

10:00	Introduction to Breakout Groups	Peter Black
--------------	--	--------------------

Break 10:15 – 10:50

Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern

Industry Meets IBCN – Breakout 10:50 – 12:50			
Partner	Topic	Facilitator	Room #
CG Oncology	Cretostimogene Translation Research Program; Current Insights and Future Directions	Peter Black, Colin Dinney	Aare
enGene	Mainstreaming Genetic Medicine	Anthony Cheung, James Sullivan, Raj Pruthi, Vikram Narayan	Panorama 3
ImmunityBio	New Combination Trials of Anktiva (IL-15 Superagonist) and Recombinant BCG and Other Agents	Cyrill Rentsch, Noah Hahn	Panorama 7
Johnson & Johnson	Drug Delivery Systems in Bladder Cancer: TAR-200 and TAR-210 Clinical Trials and Future Opportunities	Michael Kelleher, Astrid Rijken-Knol, Tilman Todenhöfer	Panorama 2
Pfizer	Unmet needs and emerging considerations in NMIBC and MIBC: Ready for Prime Time?	Bernadett Szabados, Siamak Daneshmand	Panorama 4
Photocure	Blue Light AI, HD FLEX, and the Future of Enhanced Cystoscopy	Kristine Young-Halverson, Chad McKee, Gautier Marcq	Panorama 6

Lunch break and poster view 12:50- 14:00

IBCN Speaker (chair: Roman Nawroth)

14:00	Insights from normal urothelium for cancer development	Jennifer Southgate
14:30	Discussion	

Abstract Session II (Advancements in Circulating Biomarkers)

Chairs: Sia Lindskrog, Deb Sundi		
14:50	Comprehensive characterization of the T cell receptor repertoire in bladder cancer	Nanna Kristjánsdóttir
14:59	Dynamic monitoring of circulating tumor DNA to predict prognosis in muscle-invasive bladder cancer patients after radical cystectomy	Lourdes Mengual
15:08	Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients undergoing trimodality therapy (TMT)	Kent Mouw
15:17	Clinical test design affects tumor tissue and ctDNA FGFR gene status in metastatic urothelial cancer: a prospective study	David Muller-Sartori
15:26	Circulating immune-modulators of response to neoadjuvant Nivolumab (NIVO) + Nab-paclitaxel (ABX) in Muscle Invasive Bladder Cancer (MIBC): biomarker analyses from Nure-COMBO trial	Brigida Maiorano
15:35	Investigating bacillus Calmette-Guérin induced B cell responses in patients with non-muscle invasive bladder cancer	Priyanka Yolmo

Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern

Poster Session with Wine & Snacks 15:50-18:00		
15:50	Short presentations of all posters at podium followed by group photo and poster session	Sita Vermeulen & Jeffrey Damrauer

Instructions:

All poster presenters will have the opportunity to provide a brief **1-minute** “teaser” at the podium. Each poster presenter should prepare ONE slide that highlights their poster findings and encourages attendees to visit the poster to learn more. Moderators will introduce the speaker and poster title.

Important: Please send a PDF file of your **1** slide to Aseil Eljallad (aseil.eljallad@ubc.ca) no later than September 17, 2024. Slides cannot be added during the meeting. Please name your PDF file with your poster number (which can be found in the program) and your last name [**Format: ##_LastName.pdf**].

Adjourn		
18:00	Closing words	Roman Nawroth

IBCN Dinner	
20:00	Casino Bern (Casinoplatz 1 3011 Bern)

Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern

SATURDAY, Sept 21st, 2024

***Breakfast on your own in the hotel **BEFORE** meeting

8:00	IBCN – General Assembly	Members Only
	Theme: Emerging technologies in bladder cancer	Chair: Tilman Todenhöfer
9:00	Augmented cystoscopy with deep learning	Joe Liao
9:20	The value of mpMRI to assist in decision making in MIBC	Andrea Necchi
9:40	AI/ML in bladder cancer	Jethro Kwong

Health Break 10:00 – 10:15

Keynote II		
		Chair: Lars Dyrskjøt
10:15	Development and principles of the Lund Taxonomy for bladder Cancer	Mattias Höglund
	Molecular subtyping in 2024 - ready for prime time?	
10:45	GUSTO Trial	Jon Griffin
10:52	VESPER Trial	Yves Allory
10:59	SUBTYP trial	Seth Lerner
11:06	LUMBER-NAC Trial	Saum Ghodoussipour
11:13	Panel Discussion	

Abstract Session III (Treatment Response Correlates)		
	Chairs: David Mueller, Veronika Bahlinger	
11:30	Spatial proteomics and transcriptomics reveal an altered immune cell landscape in bladder cancer patients unresponsive to BCG treatment	Trine Strandgaard
11:39	Oncolytic virotherapy expressing a novel TLR agonist and IL-15 for the treatment of non-muscle invasive bladder cancer (NMIBC)	Hardev Pandha
11:48	Quantifying intra-tumoral molecular subtype heterogeneity in MIBC from histological slides using a deep learning approach in the VESPER trial	Jacqueline Fontugne
11:57	Machine learning identifies a scar-like profile with favorable outcomes in residual bladder cancers after neoadjuvant chemo- and immunotherapy	Ewan Gibb
12:06	Comprehensive omics analysis reveals treatment-induced tumor microenvironment alterations in bladder cancer	Martina Radic
12:15	Systematic evaluation of differentially expressed genes associated with response to neoadjuvant chemotherapy in MIBC	Aymeric Zadoroznyj

Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern

Lunch & Poster View 12:30– 13:30

	Theme: ADCs: current status and future directions	Chair: Kent Mouw
13:30	ADC clinical trials update	Matt Milowsky
13:50	Mechanisms of resistance to ADCs	Markus Eckstein
14:10	ADC toxicity and management	Srikala Sridhar

Abstract Session IV (Novel Therapies and Outcome Measures in Clinical Trials)

	Chairs: Amanda Myers, Gautier Marcq	
14:40	TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or refuse neoadjuvant platinum-based chemotherapy: interim analysis of SunRISe-4	Andrea Necchi
14:49	TAR-200 in combination with cetrelimab, TAR-200 alone, or cetrelimab alone in patients with bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer: results from SunRISe-1	Michiel van der Heijden
14:58	First Translational Correlates using Urinary Genomic Disease Burden to Assess Cretostimogene Grenadenorepvec: Comprehensive Analysis from the BOND-003 Trial in BCG-Unresponsive, High Risk, Non-Muscle Invasive Bladder Cancer	Colin Dinney
15:07	EG-70 (detalimogene voraplasmid), a novel, non-viral, intravesical gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS): preclinical characterization and translation into the clinic	James Sullivan
15:16	Benefit of Whole-Pelvis Radiation for Patients with Muscle-Invasive Bladder Cancer: an Inverse Probability Treatment Weighted Analysis	Gautier Marcq
15:25	A Comprehensive Characterization of Peri-Tumoral Tertiary Lymphoid Structures in Tumors from BCG-Unresponsive Bladder Cancer Patients	Kartik Sachdeva

Awards, Wrap-Up & Closing Remarks

15:40	Awards Presentation – Peter Black
15:50	Closing Remarks, welcome to Munich 2025 (9-11 Oct) – Roman Nawroth
16:00	Adjourn

Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern

Poster overview		
#	Abstract title	Presenter
1	Retifanlimab Monotherapy as Neoadjuvant Therapy for Patients With Cisplatin (CDDP)-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder (miIBC): Results From the Multicenter OPTIMUS Umbrella Study	Necchi, Andrea
2	Investigating the role of glucocorticoid receptor signaling in cellular plasticity and bladder cancer progression	Garioni, Michele
3	abstract withdrawn	
4	Meta-analysis of genome-wide association studies of outcomes in patients with non-muscle invasive bladder cancer	Hof, Jasper
5	Anti-tumor activity of the intravesical combination of carboplatin and nab-paclitaxel in the MB49 non-muscle invasive bladder cancer model	Boillat, Sarah
6	The Prognostic and Molecular Impact of Transposable Element Expression in Bladder Cancer	Garven, Andrew
7	First-in-Human Study of TAR-210 Erdafitinib Intravesical Releasing System in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) With Select FGFR Alterations	Vilaseca, Antoni
8	Unseen Forces: Non-Coding Drivers of Bladder Cancer and Their Potential Role in Therapeutic Resistance	Banday, Rouf
9	AI-enabled bladder cancer grading: Externally validating quantitative nuclear features and demonstrating their potential to better predict time to recurrence	Berman, David
10	Urine mutation profiling differentiates age-associated field defects from pre-malignant clonality, supports a multi-hit model of carcinogenesis, and predicts urothelial cancer up to 10 years ahead of clinical diagnosis	Levin, Trevor
11	A Randomized phase ii Trial comparing single dose perioperative instillation of Intravesical Gemcitabine versus Mitomycin-C following Complete Resection of Non-Muscle Invasive Bladder Cancer: Evaluation of Efficacy and Tolerance	Nayak, Brusabhanu
12	A scalable and quantitative functional assay deciphers cisplatin-sensitive ERCC2 mutations in bladder cancer	Börcsök, Judit
13	Prognostic role of baseline levels and early changes of systemic inflammatory indexes for avelumab maintenance in metastatic urothelial carcinoma: the MeetURO25a/SAILOR study	Maiorano, Brigida Anna
14	Association of HER2neu expression status of advanced urothelial bladder cancer with other antibody-drug-conjugate targets and activating FGFR3 alterations	Bahlinger, Veronika
15	abstract withdrawn	
16	Proteomic analysis of the urothelial cancer landscape	Dressler, Franz
17	Sensitive urothelial cancer detection via high volume urine DNA analysis	Nikkola, Jussi
18	abstract withdrawn	
19	Elucidating the Response Rates to Additional Bacillus Calmette-Guerin (BCG): implications for clinical trial design	Myers, Amanda

Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern

20	Metanalysis investigating the role of the Xpert® Bladder Cancer detect assay in patients with asymptomatic microhematuria	Schmitz-Dräger, Bernd
21	Histological subtypes and divergent differentiation of urothelial carcinoma across molecular subtypes in bladder cancer: a study from the VESPER trial	Fontugne, Jacqueline
22	LncRNAs identify a subset of Ba/Sq tumors with worse prognosis and poor outcome after immunotherapy	Estrada Virrueta, Lilia
23	Recurrence patterns in a large contemporary cohort of patients with non-muscle invasive bladder cancer	Hof, Jasper
24	Pioneering novel strategies in personalized medicine for bladder cancer treatment	Lodewijk, Iris Adriana Maria
25	Prognostic Significance of Prostaglandin Synthesis in Bladder Cancer Tissue	Türker, Polat
26	Influence of immortal time bias and conditional survival on the comparison of radical cystectomy versus trimodality therapy for muscle invasive bladder cancer	Chan, Amy
27	A new drug repurposing approach based on multi-omics signatures to identify new treatment options for bladder cancer	Hoffmann, Michele J
28	T Cell Subsets of Urine Derived Leukocytes (UDLs) Serve as an Indicator of Tumor Infiltrating Leukocytes (TILs) and Reflect Immunological Sex Differences in Bladder Cancer	Sundi, Debasish
29	Bladder cancer-on-chip: A 3D model to study human urothelial tumors under physiological stretch	Kiener, Mirjam
30	abstract withdrawn	
31	Metachronous upper tract urothelial carcinoma following non-muscle invasive bladder cancer: A retrospective, multi-institutional study	Pace, Keiran
32	Transcriptomic profiles and specificity of CD4+ and CD8+ T cells present in human bladder carcinomas during BCG treatment	Brochier, Walther
33	Abstract withdrwan	
34	abstract withdrawn	
35	abstract withdrawn	
36	Extended Versus Standard Pelvic Lymphadenectomy in Radical Cystectomy: A Comprehensive 20-Year Multicenter Analysis on Survival and Recurrence	Yu, Jiwoong
37	Immunohistochemistry-based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy	Szarvas, Tibor
38	Neoadjuvant PD-1 inhibitor plus etoposide and cisplatin in neuroendocrine bladder carcinoma: a single-center, real-world experience	Qian, Lei
39	RJBLC-NEBC001: A prospective, single-arm study on neoadjuvant adebrelimab plus etoposide and cisplatin in neuroendocrine bladder carcinoma	Qian, Lei
40	Bladder Cancer: Financial Impact on the Brazilian Public Health System	Korkes, Fernando
41	Judicialization demands for bladder/ureteral cancer in the public health system in Brazil	Korkes, Fernando

Program 27th Meeting of the IBCN

September 19th – September 21st, 2024. Bern

42	Urine-based biomarkers for diagnosis of bladder cancer: Assessment of the diagnostic accuracy of urinary TERT promoter mutations, BTA stat® and UBC® rapid tests in the French DIAGURO cohort	Avogbe, Hodonou Patrice
43	Urine-based immune profiling: evaluating sample quality and feasibility	Domingos-Pereira, Sonia
44	Validation of Urinary TERT promoter mutations as a potential urine biomarker for the early detection of bladder cancer	Le Calvez-Kelm, Florence
45	Integrating genetic alterations and histopathological features for enhanced risk stratification in non-muscle invasive bladder cancer	Lillesand, Melinda
46	Role of Hypoxia-Induced Integrated Stress Response in Bladder Cancer Cell Plasticity.	Vassalakis, Julia
47	Impact of multifocal carcinoma-in-situ on the risk of tumour progression in non-muscle invasive bladder cancer patients: A retrospective, multi-institutional study	Pace, Keiran
48	In vivo validation of repurposed anti-cancer drugs for urothelial bladder cancer using the chorioallantoic membrane model	Dikmen, Onur
49	abstract withdrawn	
50	CTU radiomics-based model to distinguish HER2 expression status in bladder cancer	Shi, Ming-Jun
51	Validation of PTGR-1 expression as a Biomarker in Metastatic Urothelial Carcinoma assessed by Immunohistochemistry and Nanostring nCounter RNA detection.	Stormoen, Dag Rune
52	Urinary chemokines as potential predictive factors for BCG failure	Schneider, Anna
53	abstract withdrawn	
54	CRISPR-Cas9 Screening Using a Novel ex vivo Murine Bladder Tissue Model Identifies DDR1 as an Inhibitor of Bladder Cancer Cell Invasion	Günes, Cagatay
55	abstract withdrawn	
56	Validation of artificial intelligence-powered pathology assay and comparison to EAU 2021 guidelines on prediction of muscle invasive progression post BCG in an international 12 center cohort	Vignesh Packiam